The Prognosis of Patients After PCI：a Multi-center Study in China

Huazhong University of Science and Technology

Status: Enrolling

Conditions: Inflammation

Study type: Observational

Funder types: Other

Identifiers

NCT05614050

ChiPCI

Details and patient eligibility

About

Coronary artery disease (CAD) is caused by myocardial ischemia, hypoxia or necrosis due to coronary artery stenosis, spasm or obstruction. Although standard drug therapy can greatly improve the prognosis of patients with CAD after percutaneous coronary interventions (PCI), these patients are still at high risk of major adverse cardiovascular and cerebrovascular events (MACCE). At present, the concept of residual inflammation risk (RIR) has aroused widespread concern. RIR is an important independent risk in patients with CAD. Previous studies indicated that hsCRP ≥ 2mg / L was the definition standard of RIR in CAD in European and American people. In China, the impact of dynamic changes of hsCRP and other inflammatory factors on MACCE in PCI population remains unclear. Therefore, in this study, the investigators plan to recruit patients undergoing PCI, and observe the impact of hsCRP and other inflammatory factors on the prognosis of these patients during long term follow-up at 17 hospitals in China.

Enrollment: 2,400 estimated patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants who understand and sign the informed consent voluntarily;
• Age ≥ 18 years old and ≤ 80 years old, regardless of sex;
• The hospitalized patients with coronary heart disease undergoing PCI;
• Complete all planned PCI during hospitalization.

Exclusion criteria

• Acute, chronic or recurrent infectious diseases;
• Immune diseases or immune-related diseases;
• Long-term use of non-steroidal anti-inflammatory drugs, hormones, immunomodulatory and chemotherapy drugs;
• Pregnant women, lactating women or women of childbearing age who do not use effective contraceptive measures;
• The researchers determined that other conditions in which the patient was not suitable to participate in the clinical trial.